Arneborn P, Palmblad J
Acta Med Scand. 1982;212(5):289-92. doi: 10.1111/j.0954-6820.1982.tb03216.x.
Hospital records of 256 patients discharged with a diagnosis of agranulocytosis during 1973-78 in the Stockholm County region were reviewed. In 84 cases the neutropenia was probably caused by drugs other than cytostatics, giving an annual incidence of 0.009%. The commonest drugs were sulfonamides, thyreostatics and thenalidine. Metamizole (Dipyrone), previously the commonest cause of drug-induced neutropenia in Sweden, has not been marketed since 1973 and, as a result, only two cases were seen (the drug had been obtained abroad). Comparison of the number of cases of neutropenia with drug sales showed the highest frequency for thenalidine, followed by thyreostatics, penicillamine and sulfonamides, in that order. Only about 35% of the cases had been reported to the authorities. Nine (11%) of the patients died. It is concluded that the pattern of drugs causing neutropenia has changed in Sweden since the studies from the latter half of the 60s and that early detection of this side-effect requires directed and continuous follow-up studies.
回顾了斯德哥尔摩县地区1973 - 1978年间出院诊断为粒细胞缺乏症的256例患者的医院记录。在84例中，中性粒细胞减少可能是由细胞毒性药物以外的药物引起的，年发病率为0.009%。最常见的药物是磺胺类、抗甲状腺药和噻苯咪唑。安乃近（双吡唑酮）以前是瑞典药物性中性粒细胞减少的最常见原因，自1973年以来已不再上市，因此仅见2例（药物从国外获得）。中性粒细胞减少病例数与药物销售量的比较显示，噻苯咪唑的频率最高，其次是抗甲状腺药、青霉胺和磺胺类，顺序依次如此。只有约35%的病例已向当局报告。9例（11%）患者死亡。结论是，自60年代后半期的研究以来，瑞典引起中性粒细胞减少的药物模式已经改变，并且这种副作用的早期检测需要有针对性的持续随访研究。
